Spravato or At-Home Ketamine? How I Help Patients Choose

When patients come to me already weighing Spravato against at-home ketamine, they've usually read enough to know that both are "ketamine therapy" in some general sense and not enough to know how different the two experiences actually are. The differences aren't subtle. They affect what you pay, where you go, what your week looks like, and how the treatment fits into your life. So instead of a side-by-side comparison chart, let me walk you through how I think about this with patients in evaluation visits.

They are both ketamine, but they are not the same drug

Ketamine exists in two mirror-image forms, called enantiomers. Standard pharmaceutical ketamine, which is what we prescribe for at-home use, is a 50/50 mix of both forms (called racemic). Spravato is just one of those forms (the S-form, called esketamine) which Johnson & Johnson patented and got FDA-approved in 2019.

This matters less clinically than the marketing on either side will tell you. Both forms work through the same NMDA-receptor blockade and the same downstream neuroplasticity. There's an active research conversation about whether the R-form (which esketamine doesn't include) contributes meaningfully to the antidepressant effect. The honest answer is: probably some, but the studies are still landing, and in practice both treatments help most patients who respond. If your decision hinges on this molecular detail, you're probably overweighting it. The bigger differences are downstream.

The reason Spravato runs in clinics

Spravato is regulated under an FDA program called REMS (Risk Evaluation and Mitigation Strategy), which is the most restrictive class of post-approval safety controls. In practical terms, it means the medication can only be administered in a certified facility, by certified providers, with two hours of in-person clinical observation after each dose. You don't take Spravato home. You can't drive yourself afterward. Each session is a half-day commitment by the time you account for getting there, the dose, the monitoring, and someone driving you back.

This isn't because Spravato is uniquely dangerous. It's because it was the first ketamine product to go through formal FDA approval for depression, and the regulatory approach was understandably cautious. Racemic ketamine, the at-home version, has been used in medicine for over fifty years, was generic before any company tried to commercialize it for depression, and is prescribed off-label, which means it falls under standard physician prescribing judgment rather than a REMS program.

What this means for you, practically: Spravato is going to ask you to organize your life around clinic visits. That's not a fatal flaw if your insurance covers it well and there's a certified center nearby; it's an actual virtue if you find clinical settings reassuring. But if you're already thin on time, you live an hour from the nearest certified center, or you can't easily arrange transportation, the friction adds up over a 6-month course in a way that affects whether you actually finish treatment.

The cost conversation, honestly

Spravato is expensive. The wholesale cost runs $590-$885 per dose, and the certified facility tacks on another $100-$300 per session for the two-hour monitoring period. The standard course is twice-weekly sessions for a month, then weekly, then biweekly maintenance; annual costs reach $25,000-$40,000 before insurance. For the at-home cash pricing comparison, the gap is substantial.

The "before insurance" caveat is doing a lot of work in that number. Most commercial insurance plans cover Spravato, but the route there is hard. You'll need prior authorization documenting at least two failed antidepressant trials. Some plans require step therapy, proving you've tried specific medications first. Once approved, copays still vary widely; I've seen patients pay $50 a session and I've seen them pay $400 a session through their plan's specialty tier.

At-home ketamine is almost never covered by insurance, because it's prescribed off-label. The cash cost runs much lower because racemic ketamine is generic, there's no facility fee, and the per-session monitoring is built into the telemedicine model rather than billed separately. For most patients I see, the all-in out-of-pocket cost over six months is meaningfully less than what they'd pay in Spravato copays even with decent insurance coverage. Not always; if you have unusually good Spravato benefits, the math can flip, but usually.

The thing I encourage patients to do before they decide is run the actual numbers, not the headline numbers. Call the certified Spravato center near you. Get a quote with your specific insurance. Then compare to the at-home cash cost. The decision often becomes clearer once it's actual dollars instead of estimates.

What the experience asks of you

This is the dimension patients underweight in their initial research, and it's the one that often decides whether they finish treatment.

Spravato asks you to: drive to a certified facility for every session (twice a week for the first month), spend at least two hours there per session, arrange someone to drive you home each time, and stay clinically observed throughout. That's roughly four to five hours of your week consumed by treatment logistics during the loading phase, dropping to two to three hours weekly during maintenance. For some patients that structure is reassuring; you're in a medical setting, staff are present, the boundaries are clear. For others, particularly people who are barely holding work or caregiving together, it becomes the reason they don't complete the course.

At-home ketamine asks you to: complete a thorough screening (it's more involved than people expect), have a sober adult sitter present for the duration of each session, arrange a quiet room you've prepared, observe a 6-hour driving restriction afterward, and treat the rest of the day as recovery. Sessions happen on your schedule, in your home, but the discipline of preparing (the room, the sitter, the day blocked off) is what makes it work. Patients who treat at-home as "convenient because casual" do worse. Patients who treat it with the same seriousness as a clinic visit do well.

Neither is "easier." They ask different things of you. Which one matches your life better is a real question worth answering before you start.

How effective is each?

Both are effective. Direct head-to-head data is limited because the studies were funded by different parties and structured differently, so we're comparing across trial designs rather than within a single trial.

What we can say: Spravato's pivotal FDA trials showed about 50% response in treatment-resistant depression. Racemic ketamine, in independent academic studies, generally shows comparable or slightly higher response rates (typically 60-70% for sublingual or IV) though the studies are smaller and less standardized. Both produce rapid onset (hours to days), which is the feature that really distinguishes ketamine-class treatments from standard antidepressants.

If a patient asks me which is "more effective," I tell them the honest answer is: probably similar enough that the deciding factors are cost, access, and fit, not raw efficacy. The patient who completes their full course of either one is more likely to do well than the patient who starts the theoretically-better option and drops out after three sessions.

When I think Spravato is the better fit

If your insurance covers it well with low copays, if you live within reasonable distance of a certified center, if you specifically want clinical monitoring on-site each time, or if you have a complex medical profile that benefits from same-room observation, Spravato is a real option and I'll say so.

I also think it's the right call for patients who, on reflection, know they won't follow at-home discipline well. If you can't reliably get a sitter, won't prepare a quiet space, or know yourself well enough to admit you'll cut corners, the structure of clinic visits will protect you in ways that at-home can't.

When I think at-home is the better fit

If cost is a real constraint. If you don't live near a certified center. If your work or caregiving schedule can't absorb half-days spent in a clinic. If you genuinely respond better in your own environment than in a medical office. If you've already shown (through how you've handled prior medication adherence or therapy follow-through) that you can take the structure seriously when it's on you.

For most of the patients I see, the decision lands here. But that's selection bias: people who are weighing both and choose to talk to me are usually already leaning at-home. The patients who aren't a fit for at-home, I tell so directly, and I'm happy to point them toward Spravato programs in their area.

The decision isn't permanent

This is the thing I want to leave you with: choosing one doesn't lock you out of the other. I have patients who started with Spravato and switched to at-home after their insurance changed. I have patients who tried at-home, decided they wanted more structure, and moved to Spravato. The treatments are similar enough that experience with one transfers reasonably well to the other.

So don't agonize. Run the numbers, look at access, look honestly at what kind of treatment you'll actually follow through on, and pick. If it's not the right call, you'll know within a few sessions and you can adjust.

Frequently Asked Questions

What's the actual difference between Spravato and at-home ketamine?

Spravato is esketamine, the S-enantiomer of ketamine isolated and patented by Johnson & Johnson, FDA-approved for treatment-resistant depression in 2019, delivered as a nasal spray under in-clinic supervision. At-home ketamine is racemic (a 50/50 mix of S and R forms) taken sublingually at home. Both work through the same NMDA-receptor antagonism and downstream neuroplasticity mechanisms. Clinical efficacy is comparable. The R-form may add some therapeutic benefit (research is ongoing), but in practice both produce similar response rates.

Is Spravato covered by insurance, and is at-home ketamine?

Spravato is covered by most major insurance plans for treatment-resistant depression with prior authorization, typically requiring documentation of two failed antidepressant trials. Out-of-pocket costs after insurance vary from $0 (well-covered plans) to $200+/visit (high copays or coinsurance). At-home racemic ketamine is not covered by insurance because it's off-label, but the all-in cash price (~$400-500/month) often runs comparable to or lower than Spravato copays, and qualifies for HSA/FSA reimbursement.

How does the time commitment compare?

Spravato requires twice-weekly clinic visits during the loading phase (8 visits over 4 weeks) plus a 2-hour monitoring window after each dose under REMS supervision before you can drive. Total: roughly 4 hours per week of clinic time, plus commute. At-home ketamine is 60-90 minutes per session in your home, twice weekly during loading, with a 5-10 minute video check-in. Total: roughly 2.5-3 hours per week, with no commute and no monitoring window.

When does Spravato make more sense than at-home ketamine?

Spravato is the better fit when: you have insurance that covers it well and a REMS-certified clinic within reasonable commute, you prefer or need clinical supervision for safety reasons, you've had a poor response to oral routes, or you're managing acute suicidality where clinic-level monitoring is appropriate. At-home is the better fit when: insurance coverage is poor, you're more than 30-45 minutes from a Spravato clinic, your work or family schedule makes 4 hours/week of clinic time unworkable, or you want a more private treatment environment.

Ready to talk through your specific situation?

If you want to talk through whether at-home is right for your specific situation, here's the entry point. It's a real evaluation, not a sales gate; sometimes I tell people this isn't the right path for them and refer them to a Spravato center nearby. Either answer is the right one when it's the true one.

• Eligibility check: tovanihealth.com/eligibility (5 minutes, FL and NJ residents)
• Phone: 561-468-6981
• What you get back: an honest answer about whether at-home is the right fit, including a referral to Spravato if that fits your situation better.

Benjamin Soffer, DO — Tovani Health

Related reading: the at-home vs. clinic decision, is at-home as effective as clinic?, cost breakdown, after failed antidepressants.